Congressionally Directed Medical Research Programs (CDMRP) -- Tuberous Sclerosis Complex Research Program -- Clinical Translational Research Award

Funding Agency:
Department of Defense

The Clinical Translational Research Award supports studies that will move promising, wellfounded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but not limited to:

  • Studies moving from preclinical to clinical research and/or the reverse, analyzing human anatomical substances and/or data associated with completed clinical trials (such as correlative studies that investigate the correlation of a set of genetic and/or environmental factors with disease progression, or the effect of an intervention on the disease outcomes, etc.)
  • Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics.
  • Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research.

Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for funding and should consider other FY22 TSCRP funding opportunities.

Deadlines:
• Required Pre-Application Deadline: June 30, 2022
• Application Submission Deadline:  July 28, 2022

Agency Website

https://www.grants.gov/web/grants/view-opportunity.html?oppId=339041

Areas of Interest

The FY22 TSCRP Clinical Translational Research Award encourages applications in biomarkers, therapeutics, and patient-centered studies that address one or more of the following Clinical Translational Research Award Focus Areas:

  • Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
  • Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways and tumor microenvironment
  • Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures

Eligibility Requirements

Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as a PI on applications. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

Amount

$1,000,000

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY22 TSCRP Clinical Translational Research Award will not exceed $1,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type

Award
Grant

Eligibility

Faculty
Junior Faculty

Category

Medical
Medical - Clinical Science
Medical - Translational

External Deadline

June 30, 2022